Cochrane Abstracts
Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Ketanserin for Raynaud's Phenomenon in Progressive Systemic Sclerosis." Cochrane Abstracts, John Wiley & Sons, Inc, 2026. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/433132/all/Ketanserin_for_Raynaud&apos.
Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Abstracts. John Wiley & Sons, Inc; 2026. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433132/all/Ketanserin_for_Raynaud&apos. Accessed February 15, 2026.
Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis. (2026). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433132/all/Ketanserin_for_Raynaud&apos
Ketanserin for Raynaud's Phenomenon in Progressive Systemic Sclerosis [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2026. [cited 2026 February 15]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/433132/all/Ketanserin_for_Raynaud&apos.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis
ID - 433132
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/433132/all/Ketanserin_for_Raynaud&apos
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
